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Hepatitis C virus (HCV) uniquely requires the liver-
specific microRNA-122 for replication, yet global ef-
fects on endogenous miRNA targets during infection
are unexplored. Here, high-throughput sequencing
and crosslinking immunoprecipitation (HITS-CLIP)
experiments of human Argonaute (AGO) during
HCV infection showed robust AGO binding on the
HCV 50UTR at known and predicted miR-122 sites.
On the human transcriptome, we observed reduced
AGO binding and functional mRNA de-repression of
miR-122 targets during virus infection. This miR-
122 ‘‘sponge’’ effect was relieved and redirected to
miR-15 targets by swapping the miRNA tropism of
the virus. Single-cell expression data from reporters
containing miR-122 sites showed significant de-
repression during HCV infection depending on
expression level and site number. We describe a
quantitative mathematical model of HCV-induced
miR-122 sequestration and propose that such miR-
122 inhibition by HCV RNA may result in global de-
repression of host miR-122 targets, providing an
environment fertile for the long-term oncogenic
potential of HCV.INTRODUCTION
Hepatitis C virus (HCV) is a hepatotropic positive-strand RNA
virus of the Flaviviridae family that is a leading cause of liver dis-
ease globally, withmorbidities such as fibrosis, cirrhosis, and he-
patocellular carcinoma (Yamane et al., 2013). The long ORF of
the 9.6 kb HCV genome encodes a polyprotein processedinto ten proteins and is flanked by critical structured UTRs.
Unique to this virus is a dependence on the liver-specific
microRNA-122 (miR-122) (Jopling et al., 2005).WhereasmiRNAs
typically interact with the 30UTRs of mRNAs to promote mRNA
destabilization and/or translational repression (Bartel, 2009),
the binding of miR-122 to two binding sites (seed site S1 and
S2) in the 50UTR of HCV genomic RNA is critical for viral replica-
tion (Jopling et al., 2008; Machlin et al., 2011) by moderately
stimulating viral protein translation (Henke et al., 2008) and, in
concert with Argonaute (AGO), by stabilizing and protecting
the uncapped HCV RNA genome from degradation (Li et al.,
2013b; Sedano and Sarnow, 2014; Shimakami et al., 2012). As
the predominant miRNA in the liver, miR-122 has multiple roles
to regulate lipid metabolism (Esau et al., 2006), iron homeostasis
(Castoldi et al., 2011), and circadian rhythms (Gatfield et al.,
2009). MiR-122 knockout studies in vivo have revealed potent
anti-inflammatory and anti-tumorigenic functions (Hsu et al.,
2012; Tsai et al., 2012). Antagonizing miR-122 as an HCV thera-
peutic is a novel strategy (Lanford et al., 2010) with the first-in-
class inhibitor, miravirsen/SPC3649, currently in phase II clinical
studies (Janssen et al., 2013).
Studies of miRNA action during virus infections have been
enhanced with the advent of high-throughput methods to eluci-
date genome-wide miRNA:mRNA interaction networks bio-
chemically. Such methods (Chi et al., 2009; Hafner et al.,
2010), broadly relying on cross-linking and immunoprecipitation
(CLIP) of RNA bound to protein, have been applied to latent
Kaposi’s sarcoma-associated herpesvirus (KSHV) (Haecker
et al., 2012) and Epstein Barr virus (EBV) infections to uncover
miRNA regulatory networks involved in promoting viral latency
(Skalsky et al., 2012) and regulating cellular apoptosis (Riley
et al., 2012).
In the current study, we elucidated global miRNA:target inter-
action maps during HCV infection on host and viral RNA. We
observed AGO engagement at the HCV 50UTR miR-122 sites,
describe replication-dependent argonaute binding throughoutCell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc. 1099
viral genomic RNA, and provide evidence of miR-122 binding on
an HCV resistant to miR-122 antagonism. On the host transcrip-
tome, our results revealed globally reduced AGO binding and
specific de-repression of miR-122 targets upon virus infection.
This surprising systems-level observation suggests that HCV
RNA functionally sequesters miR-122, and exhibits a miRNA
‘‘sponge’’ effect analogous to roles proposed for competing
endogenous RNAs (ceRNA) (Salmena et al., 2011). Taken
together, our results establish an RNA virus as a specific and in-
direct regulator of miRNA activity in the cell.
RESULTS
Argonaute HiTS-CLIP of HCV Infected Cells
To study miRNA interactions during HCV infection, we either
electroporated RNA or infected Huh-7.5 hepatoma cells with
J6/JFH1-Clone2 HCV and after 48–72 hr, when most cells
were infected, performed AGO-CLIP and RNA-seq measure-
ments (Figures S1A–S1C). AGO-CLIP was performed using
linker ligation as previously described (Figures S1D–S1F) (Moore
et al., 2014). Alignment statistics for CLIP datasets presented in
this paper are summarized in Tables S2, S3, S4, and S5.
Due to known linker ligation biases in the preparation of small
RNA libraries (Zhuang et al., 2012), we used polyG tailing
(adapted from Ingolia et al., 2009) to determine miRNA abun-
dance profiles (Figure S1G), and found that miR-122 at 4.9%
is the seventh most abundant miRNA (Figure S1H and Table
S1). This correlated with previous data on miR-122 abundance
in these cells (Figures S1I and S1J). No systematic bias from
linker ligation was observed on mRNA targets due to the relative
heterogeneity of RNaseA cleavage in creating mRNA AGO foot-
prints (Figures S1K and S1L). For subsequent analysis on
mRNA-CLIP clusters, we focused on searching the top 50
seed families derived from poly-G CLIP studies, which consti-
tuted over 97% of miRNAs identified in Huh-7.5 cells.
An AGO Binding Map of HCV RNA Confirms Extensive
miR-122 Engagement
To define a small RNA interaction map on HCV and human
mRNA, CLIP reads were mapped onto the HCV and human ge-
nomes. Among the 1%–2%of CLIP readsmapping to HCV, AGO
binding sites were identified by clustering overlapping reads and
identifying statistically significant peaks above a uniformly
distributed background (Darnell et al., 2011; Licatalosi et al.,
2012). We observed major peaks in the 50UTR, E1, E2, NS5A,
and NS5B regions of the genome (Figure 1A, top). No significant
binding was observed on the negative strand (data not shown).
Notably, 50%of all AGObinding events on HCVRNAoverlapped
the known miR-122 seed sites in the 50UTR (Figures 1A and 1B).
Achieving nucleotide precision on the AGO:mRNA crosslink site
via crosslink-induced mutation site analysis (CIMS [Zhang and
Darnell, 2011]), we observed an enrichment of crosslink sites
predominantly within and immediately upstream of S2 (at posi-
tions 28 and 35) and, to a lesser degree, S1 base pairing loca-
tions (Figure 1B). The second largest peak was observed in the
HCV IRES and overlapped the pseudoknot and coding start
site (Figure 1D). No canonical 7-mer or 8-mer binding sites for
the top 50 miRNA seeds were noted in this region; however, a1100 Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc.putative non-canonical miR-122 site in the IRES (Pang et al.,
2012) may explain the observed AGO binding.
To probe the general miRNA dependence of AGO binding on
HCV RNA and to specifically enrich for miR-122-dependent
binding, we deleted Drosha fromHuh-7.5 cells to globally disrupt
most miRNA biogenesis, using a CRISPR-based genome editing
strategy (Figure S2). From CLIP in DDrosha supplemented with
miR-122 mimic to support HCV infection (Figure S2G), we
observed that binding to S1/S2 and the IRES was maintained,
and notably enhanced at NS5B binding sites (Figures 1A and
1C), both of which contain conserved miR-122 sites (Figure S3),
of which one was previously shown to be inhibitory for HCV repli-
cation (Nasheri et al., 2011). AGO binding to E1 and E2 peaks
was reduced in DDrosha cells, suggesting that a minor propor-
tion of AGO binding on HCV RNA is due to other miRNAs. While
reports have suggested that numerous miRNAs interact with
HCV RNA (reviewed in Singaravelu et al., 2014), among these
only let-7 and miR-196 families fell within the top 50 miRNAs
expressed, and no seeds from either of these families were
observed within significant AGO binding peaks. Taken together,
these data suggest that miR-122 constitutes the predominant
miRNA interaction with HCV RNA in these cells and is largely
confined to the 50UTR.
AGO Binding to miR-122 Sites on HCV RNA Occurs Early
and Is Replication Independent
To address the timing of AGO binding to HCV RNA, we per-
formed CLIP over a time course after electroporation of WT or
replication defective (GNN) RNA genomes. We observed com-
parable AGO binding at the S1/S2 sites of WT and GNNmutants
as early as 6 hr post-electroporation (Figures 1E and 1F). AGO
binding to the 50UTR in general, and to miR-122 sites in partic-
ular, remained stable throughout the WT time course but
decreased steadily for the GNN mutant. AGO binding to regions
outside the 50UTR emerged after 24 hr, were not observed in the
GNN mutant, and correlated with HCV RNA abundance over
time (Figures 1E–1G). This suggested early AGO binding to the
50UTR and additional replication or abundance-dependent low-
level AGO targeting of the viral ORF.
An HCV Resistant to miR-122 Antagonism Engages
miR-122 and AGO
To further dissect the impact of non-miR-122 AGO binding on
HCV RNA, we focused on an HCV recombinant that is resistant
to miR-122 antagonism (Li et al., 2011). This virus, for which the
first HCV 50UTR stem-loop is replaced with cellular U3 snoRNA,
lacks the S1 site but contains an intact S2 site. Upon deleting
miR-122 from Huh-7.5 cells (DmiR-122) using a CRISPR-based
strategy (Figure S2), we observed that while WT virus replication
was abolished inDmiR-122 cells, U3 virus replication was largely
unaffected (Figures 2A and 2B). Reintroducing miR-122
completely rescued WT virus replication and had a small but
consistent (2- to 4-fold) proviral effect on the U3 virus (Figures
2A and 2B), suggesting that U3 virus replication is largely miR-
122 independent. U3 virus replication could also be launched in
DDrosha cells, yet inWTcells S2p3 andp3,4mutantswere nega-
tive for HCV replication over 3 weeks, suggesting perturbation of
overlapping functions on theRNA (data not shown). InCLIPonU3
Figure 1. Argonaute Binding Maps on HCV RNA
(A) Mock-subtracted binding map of AGO-CLIP reads across HCV genomic RNA in WT or DDrosha Huh-7.5 cells. Data were normalized to total cellular and virus
read depth for comparison. Significant peaks per track are named by location and indicated by asterisks. BottomCIMS track shows location of all deletions (gray)
and statistically significant CIMS deletions (red) from the WT track.
(B) AGObinding in significant peaks fromWTHuh-7.5 cells in (A) shown as normalized read densities calculated per dataset. Datawere normalized to background
read density of non-peak regions (dashed line). Asterisks, **p < 0.01, *p < 0.05, Student’s t test. Error bars, ± SD.
(C) Schematic of a miR-122 binding model to S1 and S2 highlighting locations of CIMS deletions.
(D) Zoom in view of AGO binding from WT cells in (A) across the viral IRES into the coding sequence. IRES domains (II-IV), associated stemloops (a-d), and the
pseudoknot (pk) region are indicated. Upper track displays seeds for the top 50 miRNA seeds, previously proposed miR-122 binding (Pang et al., 2012) high-
lighted in red.
(E and F) AGO binding time course of WT (E) and replication deficient (GNN) (F) HCV post-electroporation (n = 2).
(G) Absolute qPCRmeasurements of miR-122 and HCV RNA levels at indicated time points post-electroporation (n = 3). Replication-deficient J6/JFH1-GNN and
mock controls are shown. Dashed line indicates lower limit of quantitation. Error bars, ± SD. See also Figure S3.infected Huh-7.5 cells, we observed AGO binding and crosslink
mapping at the S2 miR-122 site specifically (Figure 2C) mirroring
WT virus and indicating that the U3 viral RNA residually engages
miR-122. In the presence of increasing concentrations of miR-
122 locked nucleic acid (LNA) inhibitor, we observed a dose-
dependent decrease in AGO binding across the viral ORF, and
a significant decrease in the S2 and IRES binding locations
(Figures 2D and 2E), consistent with a limited proviral effect of
miR-122 and specific miR-122 binding to S2 and the IRES.
Furthermore, S2 and IRES binding was lost in U3 infectedDDrosha and DmiR-122 cells (data not shown). The striking
miR-122 independence of this virus points to a potential avenue
of resistance to LNA-based therapeutics in the form of recombi-
nant viruses with similarly large 50UTR stem-loops.
HCV Infection Functionally Reduces Argonaute Binding
on Host miR-122 Targets
Given thecrucial requirement ofmiR-122 forHCV replication, and
in light of the result that HCVRNA levels accumulate towithin one
log of miR-122 levels (Figure 1G), we hypothesized that the HCVCell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc. 1101
Figure 2. An HCV Mutant Resistant to miR-122 Antagonism Engages AGO and miR-122
(A and B) Time course qPCR measurements of WT-Clone2 virus (A) or U3-Clone2 virus (B) in WT cells or in DmiR-122 cells with or without 3 nM miR-122
supplementation. Error bars, ± SD.
(C) AGO binding map (top track) and CIMS locations (bottom track) across the U3 virus 50UTR corresponding to miR-122 binding at S2. Relevant CIMS deletions
are shown in gray (not significant) and red (significant). U3 snoRNA sequence is shown in green.
(D) AGO binding map across the U3 virus genome after treatment with increasing doses of LNA122. Significant peaks are named by location and indicated by
asterisks. Bottom CIMS track shows location of all deletions (gray) and significant CIMS deletions (red) for the untreated dataset.
(E) AGO binding in significant peaks from untreated U3 datasets in (D) shown as normalized read densities calculated per dataset. ****p < 0.0001, *p < 0.05, one-
way ANOVA with bonferroni correction. Error bars, ± SD.genome may act as a ‘‘sponge’’ for cellular miR-122, where viral
replicationmay exert a broadly de-repressive effect on hostmiR-
122 targets. We reasoned that this effect would be noticeable via
CLIP as reduced AGO binding of miR-122 targets upon infection
that may result in a specific increase in the expression of these
targets measured by mRNA-seq. Indeed, comparing HCV in-
fected to uninfected cells, we observed significantly reduced
AGO binding globally for mRNA targets for which a miR-122
seed was present, compared to the combined targets of the
miR-15/16 family, as a representative targetome of similar size
to the miR-122 target network, and the top 10 or the top 50
miRNA families cumulatively (Figure 3A). Significant changes in
miR-122 binding were observed for all canonical seed types (as
defined in Bartel, 2009) (Figure 3B). Additionally, the greatest
change in AGO association was observed in CLIP clusters within
30UTRs and was less significant in CDS (coding exons), 50UTRs,
and introns (Figure S4A). Notably, the 30UTR targets of other
miRNAs suggested to bind HCV RNA directly were not altered
upon HCV infection (Figure S4B). Through RNA-seq measure-
ments we observed functional de-repression of CLIP-derived
miR-122 30UTR targets after virus infection such that greater
RNA abundance was evident when compared to all miRNA tar-1102 Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc.gets (Figure 3C). Likewise, we observed significant expression
changes for all miR-122 target seed types (Figure 3D). Compared
to bioinformatic prediction using Targetscan6.2 (TS) (Lewis et al.,
2005), we found that CLIP largely complemented and expanded
upon predicted miR-122 targets (Figures S4C–S4G). 30UTR
targets identified via CLIP and predicted by TS exhibited the
greatest change in AGO binding (Figure S4C) and mRNA de-
repression (Figures S4D and S4E) compared to expressed tar-
gets unique to either search modality. Of the expressed 731
miR-122 CLIP targets of all seed types identified via CLIP, 48%
and 9% overlapped with non-conserved and conserved TS pre-
dictions, respectively (Figure S4F). Focusing on a more stringent
set of 7-mer and 8-mer seeds for CLIP data yielded even greater
overlap, such that only 5% of CLIP-derived targets were not
represented in either TS conservation category (Figure S4G).
These results highlight a broad convergence between CLIP and
bioinformatic prediction to outline a set of miR-122 targets spe-
cifically derepressed upon virus infection.
To further corroborate our CLIP observations with HCV infec-
tion, we performed CLIP after pharmacologic inhibition of miR-
122 and in DmiR-122 Huh-7.5 cells. The reduced AGO binding
on miR-122 30UTR targets during HCV infection was similar to
Figure 3. HCV Infection De-Represses Endogenous miR-122 Targets
(A) Cumulative density function (CDF) of the log2 fold change in CLIP binding between infected and uninfected cells for all 3
0UTR clusters containing indicated 7- to
8-mer seeds by family, from triplicate experiments. ‘‘Top’’ refers to the top 10 miRNA families, exclusive of miR-122. ‘‘All’’ refers to the top 50 miRNA families,
inclusive of miR-122. Two-sided K-S test p value between miR-122 and all targets shown.
(B) The mean log2 fold change (±ranges) in CLIP binding on miR-122 3
0UTR targets versus all targets during HCV infection broken down by seed type.
(C) A CDF plot during HCV infection as in (A) but measuring target mRNA expression via RNA-Seq, from duplicate experiments at 72 hr post-infection. Targets
with more than one miRNA binding site were collapsed such that no gene is represented more than once per category.
(D) The mean log2 fold change (± ranges) in mRNA expression of CLIP targets during HCV infection broken down by seed type.
(E–G) CDF plot as in (A), between treatment over control cells with LNA122 (E) or miravirsen (F) at 30 nM or genetic deletion (G) of miR-122 (DmiR-122), each from
triplicate experiments.
(H) Proportional Venn diagram showing the overlap of miR-122 targets with reduced CLIP binding across DmiR-122, LNA or miravirsen treatment, and HCV
infection conditions. Hypergeometic p value of overlap shown.
Asterisks: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, two-sided Mann-Whitney U-test. See also Figures S2 and S4.30 nM LNA122 or miravirsen treatment (Figures 3E and 3F) and
to DmiR-122 cells compared to unedited controls (Figure 3G).
Interrogating the list of 30UTR targets exhibiting reduced AGO
binding across these three conditions revealed highly significant
overlap (Figure 3H), suggesting that the effect of HCV replication
on lowering functional miR-122 levels is functionally similar to
antagonizing miR-122. The full complement of miRNA targets
identified in these studies is presented in Table S6.
Transcriptome Regulation by miR-122 Sequestration
In Vitro Is Predictive of Sequestration In Vivo
As the global effect of HCV replication on host miR-122 usage
mirrored LNA inhibition, and more profoundly miR-122 deletion,
we hypothesized that miR-122 targets as a class might be de-
repressed in human livers as a result of HCV infection. To this
end, we performed a meta-analysis of published liver biopsy mi-
croarray data related to miR-122 inhibition or HCV infection.
Comparing TS predictions for expressed miR-122 or miR-15 tar-
gets, as well as CLIP-identified miR-122 targets to all expressed
genes in microarray data from miravirsen-treated chimpanzeelivers (Lanford et al., 2010), we noted a significant de-repression
for TS or CLIP miR-122 targets compared to all genes or to
predicted miR-15 targets (Figure 4A). In this dataset, the CLIP-
identified miR-122 targetome as a group was broadly more de-
repressed than TS predictions. We performed the same analysis
comparing HCV infected versus uninfected samples from two
array datasets (Mas et al., 2009; Peng et al., 2009) and, despite
the unknown proportion of infected cells, found in both that
miR-122 target predictions were significantly de-repressed
compared to all genes or to miR-15 target predictions in both
datasets (Figures 4B and 4C). While these results cannot directly
confirm anHCV sponge effect in vivo, they do emphasize that the
overlap between CLIP results in vitro and expression results
in vivo may indicate specific de-repression of miR-122 targets
during HCV infection.
Validation of HCV-Induced miR-122 Sequestration in
Bulk and Single Cells
The results thus far describe the global characteristics of the
HCV-induced miR-122 sponge effect on the host transcriptome.Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc. 1103
Figure 4. Meta-Analysis of Published Array Data Suggests HCV-Induced Changes on the miR-122 Target Network
(A) Miravirsen pre- and post-treatment array data from four HCV infected chimpanzees (Lanford et al., 2010) was binned according to conserved 7- to 8-mer
TargetScan (TS) predictions for miR-15 or miR-122, or from miR-122 targets with CLIP support from the current study. Boxplot whiskers denote 1.5 times the
inter-quartile distance from the nearest quartile. The mean fold change in expression for miR-122 targets was compared to miR-15 targets or all genes repre-
sented on the array, where the number of genes in each bin (n) is indicated.
(B) Analysis as in (A) comparing 24 HCV-positive to 5 -negative liver biopsies (Peng et al., 2009).
(C) Analysis as in (A) comparing 41 HCV-positive with cirrhosis samples to 19 normal livers (Mas et al., 2009).
Asterisks: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns p > 0.05, two-sided Mann-Whitney U-test.We next used luciferase and fluorescent reporters of miRNA
activity to validate the HCV miR-122 sponge on individual
30UTRs. The endogenous repression of luciferase reporters con-
taining one miR-122 seed, as well as 30UTRs of CLIP-derived
miR-122 targets was enhanced upon adding additional miR-
122 and was reversed upon LNA-mediated miR-122 inhibition
(Figure 5A). We also observed seed-dependent statistically sig-
nificant de-repression of these reporters upon virus infection
(Figure 5A).
As cellular mRNA and HCV RNA expression levels can vary
widely between individual cells (Kandathil et al., 2013; Sheahan
et al., 2014), we sought to achieve a more thorough under-
standing of the HCV miRNA sponge on host miRNA targets at
a quantitative single-cell level. Previous work demonstrated
that miRNAs generate thresholds of gene expression such
that miRNA repression can be highest on low abundance tar-
gets and can be virtually non-existent on high-abundance tar-
gets. Furthermore, these thresholds can be altered upon
manipulating miRNA levels (Mukherji et al., 2011). To test
whether HCV replication could broadly impact functional miR-
122 levels, we adapted the strategy used by Mukherji et al. to
construct two-color tet-inducible fluorescent reporters of
miRNA activity amenable to flow cytometry (Mukherji et al.,
2011) (Figure 5B).
Testing reporters with N = 1 and 6 miR-122 binding sites in the
presence of miR-122 mimic, we observed miR-122 repression
that increased with N, as expected, whereas adding LNA122
decreased repression (Figure S5A–S5D). HCV infection in both
contexts resembled LNA inhibition where de-repression was
notably more pronounced in cells expressing low amounts of re-
porter, demonstrating previously reported miRNA thresholding
effects (Mukherji et al., 2011) (Figures S5A and S5C). Impor-1104 Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc.tantly, no such changes were observed for a reporter with a
p3,4miR-122 seed (‘‘N1m’’). (Figures S5E and S5F). Additionally,
we tested a reporter with a perfectly complementary miR-122
site, thus making the miRNA behave as an siRNA. This reporter
exhibited no thresholding such that mimic repression, or LNA
and HCV de-repression was observed at all expression levels
(Figures S5G and S5H). These data suggest that HCV infection
modulates functional miR-122 levels to relieve endogenous
repression on host targets in a stoichiometric manner, governed
by target expression level and the number of miRNA binding
sites.
As miR-122 levels in Huh7-derived cells are estimated to be
10-fold lower than primary adult liver tissue (Chang et al.,
2004), we next explored the HCV sponge effect in the presence
of excess miR-122. Exogenous miR-122 addition increaseed
intracellular miR-122 by up to 10-fold in Huh-7.5 cells, within
the range of miR-122 levels measured from patient liver biopsies
(Figures S6A and S6B). As no changes in HCV RNA levels were
observed, the resulting miR-122:HCV ratio went from15:1-fold
at the lowest, to over 100:1 with 30 nM of miR-122 mimic added
(Figure S6C). Testing N = 1 or AldoA 30UTR reporter constructs in
this in vivo-like context, we observed that HCV infectionwas able
to relieve 30 nM of mimic repression to untreated levels for low
but not high abundance targets (Figures 5C and 5D). The ability
for HCV to rescue excess miR-122 repression was not as pro-
nounced for the N = 4 construct (Figure 5E) whereas a reporter
containing a perfectly complementary miR-122 site was particu-
larly sensitive to rescue by HCV replication (Figure 5F). Similar,
dose-dependent results were obtained under 0.3 or 3 nM mimic
treatment for all constructs (Figures S6D–S6G). Taken together,
these results suggest that miR-122 sponging by HCV can exist in
more physiologic miR-122 concentration settings.
Figure 5. Validation of HCV-Induced De-Repression of miR-122
Targets in Bulk and Single-Cell Resolution
(A) Luciferase reporter measurements for synthetic miR-122, miR-17, or
cellular 30UTR target constructs. Data were normalized to ‘‘no oligo’’ p3,4
mutant conditions. Significance testing was performed relative to endogenous
‘‘no oligo’’ repression for each tested construct. Error bars, ± SEM. Asterisks:
***p < 0.001, **p < 0.01, *p < 0.05, ANOVA with Bonferroni correction.
(B) Two-color fluorescent reporter containing a bidirectional Tet promoter
that drives expression of blue and red fluorescent proteins (TagBFP and
TagRFP). Each fluorescent protein is tagged with a nuclear localization
sequence (NLS) to aid in flow cytometric analysis. The 30UTR of TagRFP isA Quantitative Model of miR-122 Sponging by HCV RNA
To achieve a more quantitative understanding of the HCV
sponge, we used our dose-dependent mimic and LNA reporter
systemmeasurements to expand themiRNAmodel of gene regu-
lation presented by Mukherji et al. to incorporate a competing
self-replicating viral target (Figure 6A). Here, if HCV RNA is pre-
sent at sufficiently high numbers or has relatively high-binding
strengths compared to other miR-122 targets, it acts to reduce
the available miR-122 pool, and de-represses miR-122 targets
(r, measured as TagRFP fluorescence) relative to non-targets
(r0, measured as TagBFP fluorescence) (Figure 6B). We devel-
oped a quantitative formula for HCV-induced reduction of the
miR-122 pool in this scenario (see Supplemental Information).
Assuming steady-state levels of HCV RNA at the time of mea-
surements resulted in a decrease of the model parameter q,
which governs the amount of freemiRNA in the system. The num-
ber ofmiR-122 sites is estimated by themodel parameter l that is
related to the total binding strength ofmiR-122 to a particular site.
By tuning these parameters, we accurately fitted experimental
data of endogenous miR-122 repression of reporters with
increasing numbers of miR-122 sites (Figure 6C).
To explore the effect of HCV on themiR-122 pool, we fitted the
model to experimental data with four miR-122 sites during infec-
tion (Figure 6D), and estimated the change to parameter q to
correspond to an approximate 50% reduction in available miR-
122. A similar result was obtained for the N = 4 construct in the
presence of HCV and 30 nM miR-122 mimic (Figure 6E). The
model estimated that the highest theoretical HCV levels reducing
the miR-122 pool by 90% could de-repress mRNA targets by up
to 4.5-fold for low-expressed mRNAs (Figure 6F). Synthetic re-
porter measurements agreed with model predictions for 50% re-
ductions in miR-122 levels, where de-repression was most
drastic for low expressed targets harboring multiple miR-122
sites (Figure 6G).
In similar measurements with reporters containing full 30UTRs,
we observed modest de-repression upon HCV infection with an
average change of 25% across all expression levels for the pre-
viously known targets with one miR-122 site, AldoA, PKM2, and
P4HA1, but not for CS 30UTRs (Figures 6H and S5H–S5L). The
novel CLIP-identified targets CTDNEP1, SFT2D1, MASP1 and
MAL2 behaved similarly, with all four tested being reduced
uponmiR-122mimic addition and all except MAL2 de-repressed
upon adding virus (Figures S5M–S5P). Our quantitative model
outlines several factors controlling HCV-induced de-repression
of host mRNA targets, namely, the expression level of the target
mRNA, mRNA-miR-122 binding strength, and the number of
sites on the target mRNA.
A miR-15-Dependent HCV Redirects miRNA
Sequestration
To go beyond the correlative connection between our CLIP,
RNA-seq, and modeling results, we set out to confirm theengineered to contain N binding sites for miR-122, or full 30UTRs of miR-122
targets.
(C–F) Log-log transfer functions for N = 1 (C), ALDOA 30UTR (D), N = 4 (E) or one
perfectly complementary (F) miR-122 site in the presence or absence of 30 nM
miRNA mimic and/or HCV infection.
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Figure 6. Quantitative Modeling of miR-122 Sequestration by HCV
(A) Illustration of model reactions for miR-122 dynamics, including transcription and translation of a target mRNA, binding to miR-122 and decay of mRNA
species. HCV RNA can replicate, be degraded, or bind miR-122, and functionally sequestering miR-122 and leading to de-repression of mRNA targets.
(B) Increasing amounts of HCV or a relative increase in binding strength at miR-122 sites leads to changes in single-cell gene expression as compared to
unregulated targets, with stronger effects at the low mRNA expression levels. Parameters used are fitted from data in (C). Each curve, from bottom to top
represents a 20% reduction in the available miRNA pool by HCV. Inset displays model on a linear scale.
(C) Model fitting of the steady-state approximation to experimental data while increasing the number of binding sites corresponding to changes in total binding
strength.
(D) Model fitting for the N = 4 case showing a 50% reduction in the miRNA pool by HCV modeled by a proportional change in the theta parameter.
(E) Model fitting for the N = 4 construct under 30 nM miR-122 mimic addition ± HCV infection.
(F) Increasing HCV:miR-122 binding strength or HCV RNA abundance in the model results in functional de-repression of miR-122 targets. Each curve, from
bottom to top, represents a 10% decrease in the available miR-122 pool by HCV.
(G and H) Experimental HCV induced derepression of synthetic miR-122 binding site constructs (G) or endogenous 30 UTRs with miR-122 binding sites (H). See
also Figure S5 and S6.sponge effect by swapping the miRNA tropism of the virus to
determine if the miR-122 sponge could be redirected to the
targets of another miRNA. We selected miR-15a/b, as these
miRNAs had a sufficiently altered but GC-rich seed, and main-
tained the auxiliary pairing at nucleotides 2–3 and 30–31 of the1106 Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc.viral genome (Machlin et al., 2011) (Figures 7A and S7A). In total,
miR-15a/b constituted 5.3% ± 1.2% of miRNA identified via
miRNA-CLIP, compared to 4.9% ± 2.0% for miR-122 (Table
S1 and Figure S7A). An electroporated miR-15 variant HCV lucif-
erase reporter virus (m15) was viable, and replicated to within
Figure 7. Exchanging HCV miRNA Tropism Redirects Functional
miRNA Sequestration
(A) Base pairing diagram of miR-15a onto the mutated m15 HCV RNA. Base
changes from the WT at S1 and S2 are highlighted in blue.
(B) Luciferase measurements of supernatants fromWT and m15 HCV reporter
virus electroporations (± SD). Non-replicating GNN control is shown.
(C) Dose response of WT and m15 reporter viruses following pre-treatment
with LNA inhibitors of miR-122 or miR-15a/b at indicated concentrations,
measured at 96 hr post-infection (±SD).
(D) Time course post-infection of DmiR-122 Huh-7.5 cells of indicated
viruses (±SD).one log of the WT virus after 72 hr (Figure 7B). Notably, the miR-
15 virus was resistant to increasing concentrations of LNA122
(IC50 > 50 nM) but susceptible to LNA15a/b (IC50 = 10 nM) (Fig-
ure 7C). Similar results were obtained with non-reporter viruses
throughmeasuring HCV replication, spread of infection and virus
titers (Figures S7B–S7G). Unlike WT virus, the m15 virus was
viable in DmiR-122 cells (Figure 7D), thus demonstrating com-
plete HCV replication independent of miR-122.
AGO binding on the m15 virus in Huh-7.5 cells largely mirrored
results observed with WT virus (Figure 7E, top). Interestingly, we
observed reduced AGO binding in DmiR-122 cells for the m15
virus in IRES and NS5B peaks harboring conserved miR-122
seeds, further suggesting miR-122 dependence for AGO binding
in these regions (Figure 7E and 7F).
Turning our attention to the host, we measured the effect
on the miR-15 targetome due to m15 virus replication via
RNA-seq and confirmed de-repression specific to miR-15 tar-
gets while no longer observing effects on the miR-122 target
network (Figure 7G). These results highlight the causal nature
of an HCV-induced miRNA sponge as both functional and
somewhat modular. We note that the m15 virus sponge effect
was generally weaker than for the WT virus, likely due to the
lower replication level observed and possibly to binding of
the miR-15 family member, miR-16, which shares the seed
site but may not be able to engage the m15 genome due
to lack of auxiliary pairing (Figure S7A). Modification of the
HCV 50UTR could have direct effects on viral replication, and
may explain the slight attenuation observed for the m15 virus
(Figure 7B).
To further evaluate pro- or anti-viral effects of miR-122 abun-
dance on the m15 virus, we measured m15 virus replication in
DmiR-122 cells after re-introducing miR-122 at various concen-
trations. We observed a slight but significant increase in
secreted m15 virus levels upon re-introducing miR-122 (Fig-
ure 7H). RNA levels and percent of infected cells were also
increased in m15 infected DmiR-122 cells upon restoring miR-
122 levels (Figures S7H and S7I). Conversely, we observed a sig-
nificant reduction in viral titers after LNA-122 treatment of m15
infected Huh-7.5 cells (Figure S7G). Taken together, these re-
sults suggest that miR-122 sequestration by HCV replication
confers a slightly less pro-viral cellular environment; an effect(E) AGO binding map of m15 virus infection in WT Huh-7.5 (top) or DmiR-122
Huh-7.5 cells (bottom). Data were normalized to total cellular read depth for
cross track comparison. Statistically significant peaks per track are named by
location and are indicated by asterisks.
(F) AGO binding in significant peaks from (E) shown as normalized read
densities calculated per dataset. Two-sided Student’s t test used. Error
bars, ± SD.
(G) CDF plot of the log2 fold change in mRNA expression between HCV m15
infected and uninfected cells for all 30UTR clusters containing indicated 7- to
8-mer seeds by family, from duplicate experiments at 96 hr post-infection.
‘‘Top’’ refers to the top 10 miRNA families, exclusive of miR-122 and miR-15.
‘‘All’’ refers to the top 50 miRNA families, inclusive of miR-122 and miR-15.
Two-sided K-S test p value comparing miR-15 (blue) or miR-122 (red) clusters
to ‘‘All’’ is shown.
(H) Infectivity titers of m15 virus in DmiR-122 Huh-7.5 complemented with
exogenous miR-122 at indicated concentrations. One-way ANOVA with
Bonferroni correction, whiskers, ± ranges.
Asterisks: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. See also Figure S7.
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that may be a small trade-off for the hugely beneficial role miR-
122 plays directly in the viral life-cycle.
DISCUSSION
The aim of this study was to obtain an unbiased view of the
miRNA interactome during HCV infection on both viral and
cellular targets. We provide direct biochemical evidence of repli-
cation independent AGOassociation with HCVRNA at the 50UTR
in a number of infection contexts. Our results chiefly establish
HCV RNA may act as a competitive inhibitor of miR-122 activity,
an idea closely aligned with proposed roles for ceRNAs (Sal-
mena et al., 2011). While both HCV RNA and ceRNAs share
the theme of de-repressing a miRNA regulated network by
increasing the pool of available targets through RNA expression,
they differ in their mode of interaction with miRNAs. HCV
genomic RNA critically requires miR-122 interaction to stabilize
the viral genome and stimulate translation and replication, while
most cellular miRNA targets are degraded upon encountering a
miRNA. Moreover, unlike cellular mRNA targets, HCV genomic
RNA is its own substrate for replication, and thus constitutes a
positive feedback loop to sequester additional miR-122. These
distinguishing features suggest different parameters for HCV
versus ceRNA-based sponge effects on a miRNA target
network. This is relevant in light of recent findings showing that
endogenous miR-122 repression is only relieved when ceRNAs
are forcibly expressed at super-physiological levels (Denzler
et al., 2014). As HCV RNA represented at most between 1%–
2% of CLIP reads following infection, our data suggest ceRNA
activity may occur naturally at lower expression levels. Indeed,
single-cell reporter measurements and mathematical modeling
of the mRNA, HCV, and miRNA interplay suggest that HCV is
able to de-repress host miR-122 targets, due to an approximate
2-fold reduction in available miR-122 under our experimental
levels of HCV replication. Natural viral-derived miRNA sponges
have been described previously (Cazalla et al., 2010; Lee et al.,
2013) though no examples are currently known from RNA vi-
ruses. Whether this systems-level phenomenon occurs with
other, more robust RNA virus infections remains to be explored.
The establishment of a miR-15-dependent HCV suggests that
the miR-122 sponge effect is largely dispensable for the virus in
the Huh-7.5 cell context. Indeed, we observed that LNA-122
slightly reduced m15 virus titers and that restoring miR-122 in
DmiR-122 cells increased titers, suggesting that the miR-122
sponge may reflect a trade-off for the large, positive, and direct
impact of miR-122 on WT HCV replication. Conceivably, HCV
replication may exert enough pressure on miR-122 levels to
de-repress targets such that the cellular environment is passively
altered to negatively impact viral replication. Or more actively,
there may exist miR-122 targets that act as sensors for low
miR-122 levels, and by extension, the health of the hepatocyte.
While future work will be needed to shed light on specific players
involved in this process, our data suggest that viral replication
faces a ceiling by reducing levels of an otherwise pro-viral
miRNA.
How might the HCV miR-122 sponge impact a hepatocyte?
Work with miR-122 knockout mice, which develop progressive
liver disease that spontaneously results in HCC (Hsu et al.,1108 Cell 160, 1099–1110, March 12, 2015 ª2015 Elsevier Inc.2012; Tsai et al., 2012) suggests that miR-122 tumor suppressor
activity is essential for long-term liver homeostasis. It is tanta-
lizing to speculate that miR-122 sequestration in a chronic
HCV infection may be a molecular link to the heterogeneous liver
dysfunction that characterizes HCV-induced disease. Indeed, a
number of miR-122 targets that we confirm or establish via
CLIP and reporter measurements, such as P4HA1, PKM2, and
MASP1 are known to be upregulated in fibrosis or HCC (Jung
et al., 2011; Li et al., 2013a), with MASP1 notable for being spe-
cifically linked with HCV-associated HCC (Saeed et al., 2013).
Still, there are challenges for a direct demonstration of an HCV
miR-122 sponge in vivo. Our bulk cell measurements estimate
10-fold higher miR-122 levels in primary liver tissue versus hep-
atoma cell line derivatives (105 versus 104 estimate ranges per
cell), while HCV levels per cell are estimated to range from 1 to
102 copies per hepatocyte (Kandathil et al., 2013), in contrast
to Huh7 derivatives with 103 copies per cell. Yet, we observed
functional HCV-induced de-repression in our single-cell reporter
assay after addition of miR-122 in Huh-7.5 cells to mimic levels
in vivo. Furthermore, we found specific de-repression of miR-
122 targets in microarrays from HCV infected livers and from
miravirsen-treated chimpanzees, supporting the existence of
an HCV sponge effect in vivo. Unlike the >90% infection
frequencies in Huh-7.5 cells, the percentage of infected hepato-
cytes in chronically infected patients based on in situ hybridiza-
tion of liver biopsy tissue, ranges from as low as 0.07% to as high
as 100%, with medians in the 20%–40% range (Liang et al.,
2009; Pal et al., 2006). Combined with HCV genotype, dynamic
replication variation within the liver, and host variability in innate
immune responses (Sheahan et al., 2014), a complex picture of
HCV infection emerges that would largely mask observations
of HCV sponge effects in bulk cell or tissue AGO-CLIP measure-
ments. As it remains possible that functional effects of such a
sponge may impact highly infected cells, our data highlight the
possibility of searching for transcriptome level changes to the
miR-122 target network in response to HCV infection in individ-
ual cells. The extension of CLIP and RNA-seq in single-cell and
primary contexts provides a compelling platform to address
these and other long-term disease driven changes to a miRNA
target network.
EXPERIMENTAL PROCEDURES
Culture of Cell Lines, Generation and Characterization of WT and
m15 HCV
Cell lines were cultured and generated as described in Supplemental Informa-
tion. pJ6/JFH1-Clone2, pJ6/JFH-Clone2-5AB-Ypet, and pJc1FLAG(p7-
nsGluc2A) are fully infectious HCV non-reporter and reporter viruses,
respectively, that have been previously described (Catanese et al., 2013; Hor-
witz et al., 2013; Marukian et al., 2008). To construct miR-15-dependent
viruses in both backgrounds, we used an overlap PCR mutagenesis strategy.
HCV cloning, RNA transcription, electroporation, infection, and related virus
assays are described in detail in the Supplemental Information.
Argonaute HiTS-CLIP Analysis
Argonaute CLIP was performed generally following previous work (Chi et al.,
2009), (Moore et al., 2014). Poly-G CLIP is a direct adaptation of the single
linker ligation BrdU CLIP protocol (Weyn-Vanhentenryck et al., 2014). Relevant
details pertaining to the CLIP protocol, multiplexed library preparation, and
bioinformatic analysis are described in full in the Supplemental Information.
mRNA-Seq Library Construction
mRNA-seq libraries were prepared from Trizol extracted RNA following
Illumina TruSeq protocols for poly-A selection, fragmentation, and adaptor
ligation. Multiplexed libraries were sequenced as 100 nt single-end runs on
either HiSeq-2000 or MiSeq platforms.
Luciferase Reporter Assays
Luciferase reporter vectors were cloned by inserting short oligonucleotides or
PCR amplified target 30UTRs into psiCHECK-2. The sequence of DNA oligonu-
cleotides used for cloning are found in Table S7. Huh-7.5 cells were
transfected over night with 2.56 nM final concentration LNA122 (Exiqon) or
miR-122 mimic (Thermo Fisher) using RNAi/MAX (Invitrogen). Alternatively,
cells were infected with HCV (J6/JFH1-clone2), MOI = 3 overnight. Twenty-
four hours later, cells were transfected with 1 ng/well psiCHECK-2 reporter
plasmid using Lipofectamine2000 (Invitrogen) and incubated over night before
lysis in Passive Lysis Buffer and evaluation of luciferase levels using the Dual
Luciferase Reporter Assay (Promega) on a Omega Fluorostar reader (BMG
Labtech).
Single-Cell Reporter Measurements
Construction of miR-122 fluorescent reporters largely mirrored previous work
with miR-20 (Mukherji et al., 2011). For a list of primers used in plasmid con-
struction, please refer to Table S7. For flow cytometry, cells were run on a
MACSQuant VYB flow cytometer (Miltenyi Biotec) after fixation to detect
TagBFP, TagRFP, and Ypet signals. The raw FACS data were analyzed with
FlowJo software to gate single, intact cells according to their forward
(FSC-A) and side (SSC-A) scatter profiles. HCV-positive cells were gated on
the basis of Ypet signal above uninfected background. Untransfected cells
were used to characterize the cellular autoflourescence in BFP and RFP chan-
nels, from which we subtracted the mean plus two SD of the autofluorescent
signal for each channel in transfected cells. Cells with BFP and RFP fluores-
cence levels less than 0 after background subtraction were excluded from
further analyses. Data were log-transformed and binned according to BFP
levels, and the mean RFP signal was calculated for each BFP bin.
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